pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Rinvoq
drug
save

upadacitinib tartrate ER

Marketedupdated 6mo ago
by $ABBV AbbVie Inc.
Approved
annual revenue · 2024–2024peak $6.0B
2024: $6.0B2024$6.0B
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval44 co-mentions · 22 sources
  • drugRINVOQ44 co-mentions · 22 sources
  • drugRINVOQ LQ25 co-mentions · 22 sources
  • drugupadacitinib25 co-mentions · 22 sources
  • tagSmall Molecule22 co-mentions · 22 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.

indications

investigational
IBD (Crohn's + UC)Rheumatoid Arthritis

all catalysts(19)

approval · 19
Aug 16, 2019
approval
$ABBV295.03+0.20%
7y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jul 10, 2020
approval
$ABBV295.03+0.20%
6y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 2, 2021
approval
$ABBV295.03+0.20%
5y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 14, 2021
approval
$ABBV295.03+0.20%
5y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 14, 2021
approval
$ABBV295.03+0.20%
5y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jan 14, 2022
approval
$ABBV295.03+0.20%
5y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Mar 16, 2022
approval
$ABBV295.03+0.20%
5y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 29, 2022
approval
$ABBV295.03+0.20%
5y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Oct 21, 2022
approval
$ABBV295.03+0.20%
4y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 10, 2023
approval
$ABBV295.03+0.20%
4y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
May 18, 2023
approval
$ABBV295.03+0.20%
4y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jun 22, 2023
approval
$ABBV295.03+0.20%
3y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Nov 14, 2023
approval
$ABBV295.03+0.20%
3y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 26, 2024
approval
$ABBV295.03+0.20%
3y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 26, 2024
approval
$ABBV295.03+0.20%
3y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Mar 26, 2025
approval
$ABBV295.03+0.20%
2y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 28, 2025
approval
$ABBV295.03+0.20%
2y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Aug 12, 2025
approval
$ABBV295.03+0.20%
1y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Oct 10, 2025
approval
$ABBV295.03+0.20%
1y ago
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
view all 19 catalysts →

Trials studying upadacitinib tartrate ER

  • phase4A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritisrecruitingn=100
  • phase4Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritisnot yet recruitingn=200

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 26, 2027
161 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (74)

  • Mar 9, 2038method-of-use (U-3624)US 11564922
  • Mar 9, 2038method-of-use (U-3624)US 11564922
  • Mar 9, 2038method-of-use (U-3624)US 11564922
  • Mar 9, 2038method-of-use (U-3341)US 11607411
  • Mar 9, 2038method-of-use (U-3341)US 11607411
  • Mar 9, 2038method-of-use (U-3341)US 11607411
  • Oct 17, 2036formulationUS 10202393
  • Oct 17, 2036formulationUS 10344036
  • Oct 17, 2036formulationUS 10519164
  • Oct 17, 2036method-of-use (U-3298)US 10550126
  • Oct 17, 2036method-of-use (U-3255)US 10597400
  • Oct 17, 2036formulationUS 10730883
  • Oct 17, 2036compositionUS 10981923
  • Oct 17, 2036compositionUS 10981923
  • Oct 17, 2036compositionUS 10981923
  • Oct 17, 2036formulationUS 10981924
  • Oct 17, 2036formulationUS 10981924
  • Oct 17, 2036method-of-use (U-3298)US 10995095
  • Oct 17, 2036compositionUS 11186584
  • Oct 17, 2036compositionUS 11186584
  • Oct 17, 2036compositionUS 11186584
  • Oct 17, 2036formulationUS 11198697
  • Oct 17, 2036formulationUS 11198697
  • Oct 17, 2036formulationUS 11198697
  • Oct 17, 2036method-of-use (U-3275)US 11365198
  • Oct 17, 2036method-of-use (U-3371)US 11512092
  • Oct 17, 2036method-of-use (U-3371)US 11524964
  • Oct 17, 2036method-of-use (U-3255)US 11535624
  • Oct 17, 2036method-of-use (U-3298)US 11535625
  • Oct 17, 2036method-of-use (U-3298)US 11535626
  • Oct 17, 2036compositionUS 11661425
  • Oct 17, 2036compositionUS 11661425
  • Oct 17, 2036compositionUS 11661425
  • Oct 17, 2036compositionUS 11680069
  • Oct 17, 2036compositionUS 11680069
  • Oct 17, 2036compositionUS 11680069
  • Oct 17, 2036compositionUS 11718627
  • Oct 17, 2036compositionUS 11718627
  • Oct 17, 2036compositionUS 11718627
  • Oct 17, 2036method-of-use (U-3298)US 11767326
  • Oct 17, 2036method-of-use (U-3298)US 11767326
  • Oct 17, 2036compositionUS 11773105
  • Oct 17, 2036compositionUS 11773105
  • Oct 17, 2036compositionUS 11773105
  • Oct 17, 2036method-of-use (U-3371)US 11773106
  • Oct 17, 2036formulationUS 11780847
  • Oct 17, 2036method-of-use (U-3371)US 11780848
  • Oct 17, 2036formulationUS 11787815
  • Oct 17, 2036method-of-use (U-3255)US 11795175
  • Oct 17, 2036method-of-use (U-3298)US 11976077
  • Oct 17, 2036method-of-use (U-3946)US 11993605
  • Oct 17, 2036method-of-use (U-3487)US 11993606
  • Oct 17, 2036formulationUS 12077545
  • Oct 17, 2036formulationUS 12077545
  • Oct 17, 2036formulationUS 12077545
  • Oct 17, 2036formulationUS 12091415
  • Oct 17, 2036formulationUS 12103933
  • Oct 17, 2036formulationUS 12110297
  • Oct 17, 2036compositionUS 12110298
  • Oct 17, 2036compositionUS 12110298
  • Oct 17, 2036compositionUS 12110298
  • Oct 17, 2036formulationUS 12116373
  • Oct 17, 2036formulationUS 12134621
  • Oct 17, 2036method-of-use (U-3945)US 12365689
  • Oct 17, 2036compositionUS 9951080
  • Oct 17, 2036compositionUS 9951080
  • Oct 17, 2036compositionUS 9951080
  • Oct 17, 2036formulationUS 9963459
  • Aug 16, 2033compositionUS RE47221
  • Aug 16, 2033compositionUS RE47221
  • Aug 16, 2033compositionUS RE47221
  • Jan 15, 2031compositionUS 89626294.2y
  • Jan 15, 2031compositionUS 89626294.2y
  • Jan 15, 2031compositionUS 89626294.2y

FDA exclusivities (13)

  • Apr 26, 2031ODE-481Orphan Drug (7y)4.4y
  • Apr 26, 2031ODE-481Orphan Drug (7y)4.4y
  • Apr 26, 2031ODE-481Orphan Drug (7y)4.4y
  • Apr 28, 2028I-966Indication (3y)1.4y
  • Apr 26, 2027I-946Indication (3y)161d
  • Apr 26, 2027I-946Indication (3y)161d
  • Apr 26, 2027NPPNew Product (3y)161d
  • Apr 26, 2027NPPNew Product (3y)161d
  • Apr 26, 2027I-946Indication (3y)161d
  • Apr 26, 2027NPPNew Product (3y)161d
  • May 18, 2026I-919Indication (3y)
  • May 18, 2026I-919Indication (3y)
  • May 18, 2026I-919Indication (3y)

News(10)

  • AbbVie bets up to $1.47B for Nxera’s discarded IBD program
    AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.
    biospace · 11d ago
  • AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
    AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.
    fiercebiotech · 12d ago
  • AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
    Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.
    biospace · 16d ago
  • As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
    AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…
    biospace · 27d ago
  • AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
    AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial.
    fiercebiotech · 28d ago
  • Pharma’s $500B patent problem will come in waves — not as a cliff
    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
    biopharma_dive · 1mo ago
  • 6 immunology targets to sustain a mammoth I&I market
    Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
    biospace · 1mo ago
  • North Immunology joins biotech reverse merger boom with Aethlon deal
    Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.
    biopharma_dive · 1mo ago
  • North Immunology goes public via reverse merger as eczema drug heads toward clinic
    North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.
    fiercebiotech · 2mo ago
  • Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
    Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
    fiercebiotech · 2mo ago
view all news mentions →
brand
Rinvoq
generic
upadacitinib tartrate
MOA
12.1 Mechanism of Action Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In a cell-free isolated enzyme assay, upadacitinib had greater inhibitory potency at JAK1 and JAK2 relative to JAK3 and TYK2. In human leukocyte cellular assays, upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.
indication
Vitiligo
phase
marketed
approved
2019-08-16
Data sources
openFDA · ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?